AUTHORS
Roberto Mina, Meral Beksac, MD2, Paula Rodriguez Otero, MD, PhD3, Wenming Chen4, Maria-Victoria Mateos Jr, MD, PhD5, Jian Li, MD6, Philippe Moreau Sr, MD, PhD7, Yael C. Cohen, MD8, Francesca Gay, MD, PhD9, Chang-Ki Min, MD, PhD10, Tomas Jelinek, MD, PhD11, Jing Christine Ye, M.D., MSc12, Hila Magen13, Samuel Rubinstein, MD MSCI14, Weijun Fu, MD, PhD15, Vania Hungria, MD, PhD16, Guldane Cengiz Seval, MD, PhD17, João Samuel de Holanda Farias18, Jakub Radocha, MD, PhD19, Senem Maral20, Jaszianne Tolbert, MD21, William Terry22, Christoph Heuck23, Huiling Pei24, Diego Vieyra, PhD25, Sheri Skerget26, Peter Voorhees, MD27
AFFILIATIONS
1 Winship Cancer Institute, Emory University, Atlanta, United States
2 Istinye University, Ankara University, Ankara, Turkey
3 Cancer Center Clínica Universidad de Navarra, Cima, Pamplona, Spain
4 Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
5 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
6 Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
7 University Hospital Hôtel-Dieu, Nantes, France
8 Tel-Aviv Sourasky (Ichilov) Medical Center, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel
9 University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
10 Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Rep. of South
11 University Hospital Ostrava, Ostrava, Czech Republic
12 MD Anderson Cancer Center, University of Texas, Houston, United States
13 Chaim Sheba Medical Center, Ramat Gan, Israel, Sackler Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
14 University of North Carolina School of Medicine, Chapel Hill, United States
15 Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
16 Clinica Médica São Germano, Sao Paulo, Brazil
17 Ankara University Faculty of Medicine, Ankara University,, Ankara, Turkey
18 Liga Paranaense de Combate ao Câncer (LPCC), Curitiba, Parana, Brazil
19 University Hospital Hradec Kralove, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
20 Medipol Mega University Hospital, Istanbul, Turkey
21 Johnson & Johnson, Spring House, United States
22 Johnson & Johnson, Spring House, United States
23 Johnson & Johnson, Spring House, United States
24 Johnson & Johnson, Titusville, United States
25 Johnson & Johnson, Spring House, United States
26 Johnson & Johnson, Spring House, United States
27 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, United States
ABSTRACT
Introduction: In the phase 3 MonumenTAL-3 study (NCT05455320), Tal (anti-GPRC5D bispecific antibody) plus Dara and Pom (Tal-DP) and Tal plus Dara (Tal-D) significantly reduced the risk of disease progression or death by 67-72% with a similar or more favorable infection profile vs. Dara plus Pom and dexamethasone (DPd) in pts with RRMM and ≥1 prior line of therapy (LOT). Due to minimal expression of GPRC5D on normal B cells, Tal preferentially targets myeloma cells, sparing healthy B cells and residual normal plasma cells. In later line RRMM, Tal monotherapy preserved humoral immune function, which may contribute to the lower observed rates of grade (gr) 3/4 infections relative to reports with BCMA-directed therapies. Here, we characterize the infection profile and parameters of humoral immunity in pts from MonumenTAL-3.
Methods: Pts with RRMM and ≥1 prior LOT were randomized 1:1:1 to Tal-DP, Tal-D or DPd. Tal was given 0.8 mg/kg every other week (Q2W), preceded by step-up dosing during cycle (C) 1, and Dara 1800 mg once per week from C1, reduced to Q2W at C3 and every 4 weeks (Q4W) at C7. A switch to Tal 0.8 mg/kg Q4W was permitted at C5-6 with ≥VGPR and was required from C7 with ≥PR. In Tal-DP, Pom 2 mg was administered daily (QD) on D1–21 from C2 and could be increased to 4 mg QD from C3 at investigator discretion. DPd was administered per established schedules (pts received Pom 4 mg from C1). Treatment (tx) C were 28 days. Infection prophylaxes were administered per institutional guidelines. This analysis assessed incidence and severity of infections, neutrophil and B-cell counts, and incidence of hypogammaglobulinemia over time.
Results: Among 864 randomized pts, 833 (Tal-DP, n=276; Tal-D, n=274; DPd, n=283) received the assigned study tx and were included in safety analyses. Median follow-up was 24.6 months. Rates of any gr infections (gr 3-4) were 87.3% (37.7%) in Tal-DP, 84.3% (29.2%) in Tal-D, and 83.0% (42.4%) in DPd, with gr 5 infections in 0.7%, 1.5%, and 1.8%, respectively. Rates of opportunistic infections were 16.3% (Tal-DP), 17.9% (Tal-D), and 12.0% (DPd). Rates of gr ≥3 infections were highest in the first 6 months of tx (Tal-DP, 27.5%; Tal-D, 24.1%; DPd, 25.1%) and then declined. Similarly, gr ≥3 cytopenia rates were highest in the first 6 months across arms (Tal-DP, 85.5%; Tal-D, 49.3%; DPd, 87.6%) and then generally declined. Throughout follow-up, any gr neutropenia (gr 3-4) was observed in 84.1% (76.8%), 40.9% (29.2%), and 90.5% (86.6%) of pts in Tal-DP, Tal-D, and DPd; any gr lymphopenia (gr 3-4) occurred in 35.9% (31.2%), 29.9% (24.8%), and 25.4% (17.7%), respectively. A sharp decrease in mean neutrophil counts was observed in C1 and C2 in DPd and C2 in Tal-DP, corresponding to initial exposure to Pom, which has known myelosuppressive effects. In Tal-D, mean neutrophil counts remained close to baseline throughout tx. CD19+ B-cell counts (% change from baseline) showed tx-specific kinetics, with transient reductions and near-baseline recovery in Tal-D (−35.7% at C1D22; −7.8% at C12D1, C12D1 not significant vs baseline) and later reductions and possible delayed recovery in Tal-DP (−56.6% at C6D1; −45.6% at C12D1); a reduction was observed with DPd (–64.9% at C1D22), but data beyond C3D1 are limited. The overall incidence of hypogammaglobulinemia, as assessed by TEAEs or post-baseline IgG <400 mg/dL, was 81.2% (Tal-DP), 68.2% (Tal-D), and 62.2% (DPd); incidence during the first 6 months was 73.6%, 59.1%, and 46.6% in Tal-DP, Tal-D, and DPd, respectively, and decreased by months 18-24 to 36.3%, 31.3%, and 43.0%. Overall, 63.4% (Tal-DP), 56.2% (Tal-D), and 36.7% (DPd) received ≥1 dose of immunoglobulin replacement therapy with hypogammaglobulinemia.
Conclusions: The infection profiles of Tal-DP and Tal-D were similar to or more favorable than DPd. Gr ≥3 infections peaked during the first 6 months of tx and then declined, mirroring observed rates of cytopenias and hypogammaglobulinemia. B-cell counts were moderately and transiently reduced with Tal-D, recovering to near baseline by C12. Findings suggest Tal-D minimally impacts B cells and allows preservation of humoral immunity, which may contribute to the improved infection profile compared with other emerging tx options in early line RRMM. These data support consideration of Tal-D ± Pom as highly effective, off-the-shelf tx options in early-line RRMM, particularly in pts with significant infection history or risk.
DISCLOSURES
Roberto Mina: Johnson and Johnson, Pfizer, Regeneron, Sanofi, GSK, Abbvie, Roche - Honoraria; Johnson and Johnson, Pfizer, Regeneron, Sanofi, GSK, Abbvie, Roche - Consultancy (Includes expert testimony)